The prescription drugs you take spend plenty of time on the drawing board before they end up in your medicine cabinet But the research work doesnt necessarily stop then Since  the Food and Drug Administration   to require drugmakers to continue studying the safety of their pills or other medicines as a condition for approving them in the first place Before then the studies were largely voluntary and many never got done So hows the mandatory approach going Kevin Fain   at Johns Hopkins Bloomberg School of Public Health and some colleagues took a look at the fiveyear period ending in  We wanted to see since the new law was passed what were the new trends in the way the studies were carried out he tells Shots For starters before the FDA got new powers there were over a thousand studies  more than half of those the agency expected to be performed that hadnt been started by drugmakers That number fell to  studies or about  percent in  Progress But thats still a fairly large number Fain says The proportion of tardy starts to studies ordered by FDA since the agency got mandatory powers has increased steadily and stood at  or about  percent in  More of the old studies got finished though none of the newly mandatory ones had been Fain and his colleagues wrote that despite some gains in studies initiated and fulfilled our analysis reinforces continued concerns about the status of prescription drug postmarketing studies in the United States The   appears in   a journal of the American Medical Association Now that the FDA studies are mandatory When a company misses the agreedupon deadlines and rules for a post marketing study it can land in hot water The FDA sent a sharp   to drugmaker Merck for failing to stay on schedule with a postmarketing study for the Type  diabetes medicines   and   for instance